|
Market Closed -
Hong Kong S.E.
11:08:31 24/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 11.39 HKD | -2.40% |
|
+1.06% | -4.85% |
| 09-04 | Simcere Pharma's Yingmule Gets China Marketing Approval for RSV Prevention | MT |
| 09-03 | Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Yingmule in China | CI |
Company Valuation: Simcere Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,030 | 3,965 | 2,254 | 2,273 | 3,992 | 3,821 | - | - |
| Change | - | 30.84% | -43.14% | 0.81% | 75.65% | -4.28% | - | - |
| Enterprise Value (EV) 1 | 2,944 | 3,802 | 2,173 | 2,151 | 3,637 | 3,624 | 3,681 | 3,789 |
| Change | - | 29.15% | -42.86% | -1% | 69.08% | -0.35% | 1.59% | 2.94% |
| P/E | 12.6x | 28.6x | 22.6x | 23x | 19.9x | 14.5x | 12.6x | 10.6x |
| PBR | 2.97x | 3.84x | 2.21x | 2.37x | 2.84x | 2.4x | 2.1x | 1.84x |
| PEG | - | -0.8x | -0.9x | 3.11x | 0.2x | 0.5x | 0.8x | 0.6x |
| Capitalization / Revenue | 3.86x | 4.31x | 2.46x | 2.48x | 3.56x | 2.52x | 2.24x | 1.87x |
| EV / Revenue | 3.75x | 4.13x | 2.37x | 2.35x | 3.24x | 2.39x | 2.16x | 1.85x |
| EV / EBITDA | 11x | 24.1x | 15.3x | 13.2x | 12.9x | 10.8x | 9.31x | 8.32x |
| EV / EBIT | 16.5x | 30.3x | 22x | 18.4x | 16.1x | 10.6x | 11.8x | 9.67x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 3 | 0.15 | 0.16 | 0.16 | 0.16 | 0.18 | 0.3605 | 0.4092 | 0.4814 |
| Rate of return | 2.05% | 1.56% | 2.62% | 2.4% | 1.67% | 3.61% | 4.1% | 4.82% |
| EPS 3 | 0.58 | 0.36 | 0.27 | 0.29 | 0.54 | 0.6886 | 0.7932 | 0.9412 |
| Distribution rate | 25.9% | 44.4% | 59.3% | 55.2% | 33.3% | 52.4% | 51.6% | 51.1% |
| Net sales 1 | 785.2 | 919.9 | 917.9 | 915.2 | 1,122 | 1,516 | 1,703 | 2,045 |
| EBITDA 1 | 267 | 158.1 | 141.9 | 163.5 | 280.9 | 336.3 | 395.5 | 455.5 |
| EBIT 1 | 178.1 | 125.6 | 98.87 | 117 | 225.7 | 341.9 | 312.8 | 391.9 |
| Net income 1 | 236.7 | 135.8 | 99.28 | 101.1 | 188.8 | 256.7 | 303.5 | 361.6 |
| Net Debt 1 | -85.96 | -162.3 | -81.83 | -121.8 | -355.3 | -197.3 | -139.7 | -31.68 |
| Reference price 3 | 7.324 | 10.279 | 6.109 | 6.672 | 10.757 | 9.985 | 9.985 | 9.985 |
| Nbr of stocks (in thousands) | 2,628,291 | 2,660,377 | 2,616,723 | 2,486,321 | 2,595,698 | 2,568,199 | - | - |
| Announcement Date | 3/24/22 A | 3/31/23 A | 3/20/24 A | 3/24/25 A | 3/25/26 A | - | - | - |
1CNY in Million2USD in Million3CNY
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.5x | 2.39x | 10.77x | 3.61% | 3.82B | |
| 34.41x | 6.46x | 22.39x | 0.92% | 46.71B | |
| 15.9x | 1.97x | 8.74x | 1.7% | 36.9B | |
| 28.06x | 4x | 16.57x | 0.58% | 12.18B | |
| 26.92x | 3.26x | 16.91x | 0.94% | 11.66B | |
| 18.58x | 3.37x | 11.75x | 3.79% | 8.97B | |
| 30.1x | 3.94x | 18.34x | 0.15% | 7.29B | |
| 9.32x | 2.15x | 5.57x | 4.76% | 7.21B | |
| 15.18x | 2.01x | 6.67x | 3.28% | 7.09B | |
| Average | 21.44x | 3.28x | 13.08x | 2.19% | 15.76B | |
| Weighted average by Cap. | 24.44x | 3.94x | 15.05x | 1.62% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 2096 Stock
- Valuation Simcere Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
